Skip to main content
. Author manuscript; available in PMC: 2011 May 10.
Published in final edited form as: Nat Med. 2010 Jul 8;16(8):903–908. doi: 10.1038/nm.2187

Figure 1.

Figure 1

Msi2 is expressed in HSCs, and its depletion reduces engraftment in vivo. (a) Quantitative RT-PCR of Msi2 expression in purified hematopoietic populations. SLAM, CMP, common myeloid progenitor; GMP, granulocyte monocyte progenitor; MEP, myeloerythroid progenitor; B, T, lymphocytes. Error bars represent s.e.m. for at least four experiments. (b) Strategy for Msi2 shRNA knockdown in vivo. Viral vectors carrying control scrambled shRNA (Csh) or shRNAs targeting Msi2 (Msh) along with EGFP were transduced into LSK cells followed by transplant into lethally irradiated mice (red bolts). (c) Relative engraftment of whole peripheral blood (PB) and purified bone marrow stem and progenitor cell populations (LSK, Linlow Sca+ c-Kit+; long-term HSC, LSK CD34+; LK, LinlowSca−c-Kit+) by cells infected with shRNA (Msh or Csh at 6 weeks after transplant. The ratio of EGFP+ cells in the indicated populations is relative to input (representative of three independent transplants and at least eight mice; NS, not significant, +P < 0.05, *P < 0.01, statistical nomenclature used throughout subsequent figures). (d) Representative flow cytometric analysis of bone marrow stem and progenitor cells from engrafted mice at 6 weeks after transplant.